Verona Pharma Plc ADR (NASDAQ: VRNA) on Friday, soared 4.12% from the previous trading day, before settling in for the closing price of $61.67. Within the past 52 weeks, VRNA’s price has moved between $11.39 and $63.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.71% annually for the last half of the decade. The company achieved an average annual earnings per share of -177.78%. With a float of $70.26 million, this company’s outstanding shares have now reached $81.83 million.
In an organization with 79 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 80.41%, operating margin of -2370.63%, and the pretax margin is -2352.52%.
Verona Pharma Plc ADR (VRNA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verona Pharma Plc ADR is 15.79%, while institutional ownership is 71.65%. The most recent insider transaction that took place on Dec 05 ’24, was worth 3,205,226. In this transaction President and CEO of this company sold 640,264 shares at a rate of $5.01, taking the stock ownership to the 14,367,552 shares. Before that another transaction happened on Dec 06 ’24, when Company’s President and CEO sold 162,800 for $5.01, making the entire transaction worth $815,400. This insider now owns 14,204,752 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -177.78% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Verona Pharma Plc ADR (VRNA) is currently performing well based on its current performance indicators. A quick ratio of 13.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 925.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.94, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was inferior than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.93%. Additionally, its Average True Range was 2.79.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 96.60%, which indicates a significant increase from 89.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.43% in the past 14 days, which was lower than the 49.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.54, while its 200-day Moving Average is $30.97. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $66.03. Second resistance stands at $67.85. The third major resistance level sits at $70.21. If the price goes on to break the first support level at $61.86, it is likely to go to the next support level at $59.50. Assuming the price breaks the second support level, the third support level stands at $57.68.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
Market capitalization of the company is 5.25 billion based on 80,440K outstanding shares. Right now, sales total 0 K and income totals -54,370 K. The company made 5,620 K in profit during its latest quarter, and -42,960 K in sales during its previous quarter.
